REG - SkinBioTherapeutics - Appointment of Senior Croda VP as Board Advisor

SkinbiotherapeuticsAnnouncement

29/07/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240729:nRSc1367Ya&default-theme=true

RNS Number : 1367Y  SkinBioTherapeutics PLC  29 July 2024

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Senior Croda Vice President joins SkinBioTherapeutics as

Cosmetic Science / Customer Alliances Advisor to the Board

Recognised as one of Croda's senior researchers in cosmetic ingredients

29 July 2024 - SkinBioTherapeutics plc (AIM: SBTX), a life science company
focused on skin health, announces the appointment of Dr Surinder 'Dass' Chahal
as Cosmetic Science / Customer Alliances Advisor to the Board.

Dr Chahal has been closely involved with SkinBioTherapeutics since the signing
of the commercial and manufacturing agreement in November 2019 between
SkinBioTherapeutics and Croda's Consumer Care division, Sederma, which is the
specialist in bioactive ingredients for the cosmetics industry. His role will
be the interface with Croda as the partnership moves into commercialisation.
He will also advise on cosmetic science and assist the Company in strategic
alliances with other multinationals.

Dr Chahal's career at Croda International PLC (Croda or the Group), one of the
world's leading speciality ingredients manufacturers, has spanned over 37
years. He joined Croda in 1987, initially leading cosmetic protein innovation
at the Group, then moved onto a variety of roles including Enterprise
Technologies which involved open innovation, technology investment, and he
went on to establish Croda's biotechnology research group. In 2014 he was
appointed to Croda's Global Personal Care Board as Vice President Research
& Development, then was appointed as VP Long-Term Innovation covering
strategic research and technology acquisition.

He rose to become part of the Long-Term Innovation group as VP Customer
Alliances (Technology Development) working as part of the CSO's senior
technology team across all Croda businesses. He is recognised as one of
Croda's senior researchers in the field of cosmetic ingredients.

Dr Chahal has a B.Sc. (Hons) Chemistry and a PhD in Chemistry and Chemical
technology from the University of Bradford.

Martin Hunt, Chairman of SkinBioTherapeutics, said:

"We are absolutely delighted to have Dass act as a senior advisor to the
Board. He has had a distinguished career at Croda across a variety of roles,
each of which enables him to provide valuable insight and advice to us as we
develop and commercialise our various business pillars. We have got to know
him through our partnership with Croda and he has been instrumental in
building the strong relationship that we have with both the Croda and Sederma
teams. We are very much looking forward to having him as part of the advisory
team."

Dr Chahal added:

"I have been a great supporter of the team at SkinBioTherapeutics ever since I
first saw the Skinbiotix technology and realised its potential across multiple
segments of skin healthcare. The Company may be relatively small compared to
Croda, but it has achieved a tremendous amount in a short period. As I
complete my career at Croda, I am delighted to still be involved with the
SkinBioTherapeutics team and its technology."

-Ends-

The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No.
596/2014.

For more information please contact:

 

 SkinBioTherapeutics plc                            +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

 Manprit Randhawa, CFO

 Cavendish Capital Markets Limited                  +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson (Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis, Tamar Cranford-Smith (Sales)

 Vigo Consulting (financial press)                  +44 (0) 20 7390 0230

 Rozi Morris                                        SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AxisBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDBGDRIDDDGSI